News Home

Is Cara Therapeutics Inc (CARA) Stock at the Top of the Biotechnology Industry?

Thursday, January 06, 2022 03:30 PM | InvestorsObserver Analysts
Is Cara Therapeutics Inc (CARA) Stock at the Top of the Biotechnology Industry?

Cara Therapeutics Inc (CARA) is around the top of the Biotechnology industry according to InvestorsObserver. CARA received an overall rating of 58, which means that it scores higher than 58 percent of all stocks. Cara Therapeutics Inc also achieved a score of 91 in the Biotechnology industry, putting it above 91 percent of Biotechnology stocks. Biotechnology is ranked 93 out of the 148 industries.

Overall Score - 58
CARA has an Overall Score of 58. Find out what this means to you and get the rest of the rankings on CARA!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Cara Therapeutics Inc Stock Today?

Cara Therapeutics Inc (CARA) stock is trading at $11.69 as of 3:29 PM on Thursday, Jan 6, an increase of $0.02, or 0.13% from the previous closing price of $11.67. Volume today is below average. So far 166,171 shares have traded compared to average volume of 530,207 shares. The stock has traded between $11.50 and $11.93 so far today. Click Here to get the full Stock Report for Cara Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App